PLARIUM
2.4.2020 15:02:07 CEST | Business Wire | Press release
Plarium, a leading developer of mobile, social, and web-based games with more than 290 million players worldwide, is proud to announce the launch of its latest genre-defining casual adventure title, Undersea Solitaire Tripeaks , on Android and iOS. This story-driven game offers the excitement of Solitaire Tripeaks immersed in an engrossing narrative blended with item collection and town-designing features.
The game takes place in the typically idyllic undersea town of Rocky Bottom which has been blown to pieces by a nasty whirlpool. Players must earn gems through their sweet solitaire skills to help Alfred the Crab and his fishy friends rebuild the town and make it bigger than ever before! Along the journey, players will uncover ancient artifacts, host fashion shows, welcome new residents, solve crimes, and much more.
“Plarium has been developing narrative-driven games in the strategy and RPG genres for many years, and we see a strong demand from our casual audiences for the same type of experience,” says Oleg Yakovlev, game producer at Plarium. “This is why we focused on building the first game to blend Solitaire mechanics, a narrative-driven metagame, and town customization gameplay to give players a new challenge unlike anything they have seen before in this genre!”
Undersea Solitaire Tripeaks features 30+ animated 3D characters and over 2000 intricately designed levels with a variety of gameplay mechanics to keep players engaged and entertained. Key gameplay elements include:
- The most ‘blockers’ and ‘boosters’ of any solitaire game: Undersea Solitaire Tripeaks has 15+ unique blockers and 6 boosters to offer players endless challenges.
- 600+ exciting story quests: Players will work alongside a diverse cast of characters to help grow Rocky Bottom into a bustling place with a circus, amphitheater, theme park, and more.
- Epic Challenges Every Day of the Week: Undersea Solitaire Tripeaks features a host of special Solitaire events, daily missions, and much more.
- Thousands of town customization options: Players can rebuild Rocky Bottom just the way they want.
Undersea Solitaire Tripeaks is now available for users worldwide in English, French, German, Italian, Japanese, Korean, Russian, Spanish, Turkish, Traditional Chinese, Simplified Chinese, and Portuguese. It can be accessed through the App Store and Google Play .
About Plarium
Founded in 2009, Plarium Global Ltd. is dedicated to creating the best mobile and social experience for hardcore and casual gamers worldwide. With over 290 million registered users, we're proud to be consistently ranked among Facebook’s top hardcore game developers. Plarium employs more than 1400 individuals and is headquartered in Israel with eight offices and development studios across Europe and the United States. Our games are available on iOS, Android, and Plarium Play, as well as all major social networks, including Facebook, VKontakte, Odnoklassniki and Mail.ru and web browsers. Plarium was acquired by Aristocrat in October 2017 and operates as a wholly owned subsidiary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom